Tenax Therapeutics, Inc. (TENX) is a publicly traded Healthcare sector company. As of July 26, 2026, TENX trades at $14.53 with a market cap of $385.41M and a P/E ratio of -10.66. TENX moved -0.99% today. Year to date, TENX is +19.20%; over the trailing twelve months it is +137.81%. Its 52-week range spans $4.63 to $19.40. Analyst consensus is strong buy with an average price target of $37.40. Rallies surfaces TENX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Tenax to Showcase Phase 3 LEVEL Trial Data at ESC Congress August 29: Tenax Therapeutics will present Phase 3 LEVEL trial data on oral levosimendan at ESC Congress on August 29 after enrolling 230+ PH-HFpEF patients by March 2026. A blinded sample-size re-estimation showed >90% power to detect a 25 m change in 6MWD, and the company expects topline results in August 2026.
| Metric | Value |
|---|---|
| Price | $14.53 |
| Market Cap | $385.41M |
| P/E Ratio | -10.66 |
| EPS | $-1.34 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.40 |
| 52-Week Low | $4.63 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-52.60M |
| Gross Margin | 0.00% |
6 analysts cover TENX: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $37.40.